A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Stoke Therapeutics (NASDAQ:STOK) over the past three months, with a majority being bullish. The average 12-month price target is $24.2, with a high of $35.00 and a low of $20.00. Recent financial performance shows challenges in revenue growth and net margins, but the company maintains strong financial management with low debt.
June 28, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stoke Therapeutics has received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $24.2, down from a previous $25.00. The company faces revenue growth challenges but maintains strong financial management with low debt.
The mixed analyst ratings and slight decline in the average price target suggest a neutral short-term impact on the stock price. While the company faces revenue growth challenges, its strong financial management and low debt provide a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100